NASDAQ:PRQR - ProQR Therapeutics Stock Price, Price Target & More

$3.55 -0.20 (-5.33 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$3.55
Today's Range$3.50 - $3.70
52-Week Range$2.75 - $6.90
Volume43,212 shs
Average Volume75,331 shs
Market Capitalization$113.10 million
P/E Ratio-1.83
Dividend YieldN/A
Beta0.5

About ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics logoProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company has a research collaboration agreement with Galapagos N.V. to discover Axiomer Editing Oligonucleotides against fibrosis targets. ProQR Therapeutics N.V. has a partnership agreement with Foundation Fighting Blindness to develop QR-421a for usher syndrome 2A caused by an exon 13 mutation of the causative USH2A gene. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000

Debt

Debt-to-Equity Ratio0.13%
Current Ratio5.95%
Quick Ratio5.95%

Price-To-Earnings

Trailing P/E Ratio-1.83
Forward P/E Ratio-2.32
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book2.55

Profitability

EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-114.59%
Return on Assets-86.21%

Miscellaneous

Employees133
Outstanding Shares31,860,000

How to Become a New Pot Stock Millionaire

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.01. View ProQR Therapeutics' Earnings History.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 16th 2018. View Earnings Estimates for ProQR Therapeutics.

What price target have analysts set for PRQR?

4 brokerages have issued 1-year target prices for ProQR Therapeutics' stock. Their predictions range from $4.50 to $40.00. On average, they anticipate ProQR Therapeutics' stock price to reach $19.1250 in the next twelve months. View Analyst Ratings for ProQR Therapeutics.

Who are some of ProQR Therapeutics' key competitors?

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the folowing people:
  • Mr. Daniel A. de Boer, Chief Exec. Officer and Member of Management Board (Age 35)
  • Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Corp. Sec. & Member-Management Board (Age 54)
  • Ms. Smital Shah, Chief Financial Officer (Age 42)
  • Mr. Joost Clement, Director of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property

Has ProQR Therapeutics been receiving favorable news coverage?

Headlines about PRQR stock have been trending positive on Sunday, Accern reports. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a daily sentiment score of 0.28 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 43.96 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (8.30%) and PRUDENTIAL FINANCIAL INC (8.30%). View Institutional Ownership Trends for ProQR Therapeutics.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $3.55.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $113.10 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 133 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


MarketBeat Community Rating for ProQR Therapeutics (PRQR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ProQR Therapeutics (NASDAQ:PRQR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for ProQR Therapeutics in the last 12 months. Their average twelve-month price target is $19.1250, suggesting that the stock has a possible upside of 438.73%. The high price target for PRQR is $40.00 and the low price target for PRQR is $4.50. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.1250$24.00$24.00$19.1250
Price Target Upside: 438.73% upside700.00% upside700.00% upside196.51% upside

ProQR Therapeutics (NASDAQ:PRQR) Consensus Price Target History

Price Target History for ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ:PRQR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018Chardan CapitalInitiated CoverageBuy$4.50LowView Rating Details
9/26/2017Leerink SwannReiterated RatingOutperform$10.00 -> $12.00HighView Rating Details
9/26/2017HC WainwrightReiterated RatingBuy$40.00HighView Rating Details
9/26/2017JMP SecuritiesBoost Price TargetMkt Outperform -> Outperform$14.00 -> $20.00HighView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

ProQR Therapeutics (NASDAQ:PRQR) Earnings History and Estimates Chart

Earnings by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ:PRQR) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.53 EPS
Next Year EPS Consensus Estimate: $-1.32 EPS

ProQR Therapeutics (NASDAQ PRQR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018($0.48)N/AView Earnings Details
2/28/2018Before Market($0.45)($0.46)$0.35 millionViewN/AView Earnings Details
11/20/2017Before Market($0.52)($0.49)$0.35 millionViewN/AView Earnings Details
8/16/2017Q2 2017($0.53)($0.52)ViewN/AView Earnings Details
5/17/20173/31/2017($0.50)($0.48)$0.32 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.48)($0.41)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.57)($0.48)ViewN/AView Earnings Details
8/17/2016Q2 2016($0.43)($0.48)ViewN/AView Earnings Details
5/18/2016Q1($0.41)($0.4950)$0.22 millionViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.2870)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ProQR Therapeutics (NASDAQ:PRQR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ProQR Therapeutics (NASDAQ PRQR) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 36.12%
Insider Trading History for ProQR Therapeutics (NASDAQ:PRQR)
Insider Trading History for ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ PRQR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

ProQR Therapeutics (NASDAQ PRQR) News Headlines

Source:
DateHeadline
ProQR Therapeutics (PRQR) Given Consensus Rating of "Buy" by BrokeragesProQR Therapeutics (PRQR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 22 at 7:42 AM
Zacks Investment Research Lowers ProQR Therapeutics (PRQR) to HoldZacks Investment Research Lowers ProQR Therapeutics (PRQR) to Hold
www.americanbankingnews.com - April 21 at 7:06 AM
Zacks Investment Research Upgrades ProQR Therapeutics (PRQR) to "Buy"Zacks Investment Research Upgrades ProQR Therapeutics (PRQR) to "Buy"
www.americanbankingnews.com - April 18 at 11:44 AM
Will ProQR Therapeutics (PRQR) Continue to Surge Higher?Will ProQR Therapeutics (PRQR) Continue to Surge Higher?
www.zacks.com - April 18 at 9:41 AM
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing TechnologyProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
finance.yahoo.com - April 10 at 10:07 AM
ProQR Therapeutics (PRQR) Stock Rating Upgraded by Zacks Investment ResearchProQR Therapeutics (PRQR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 8 at 8:37 AM
Chardan Capital Initiates Coverage on ProQR Therapeutics (PRQR)Chardan Capital Initiates Coverage on ProQR Therapeutics (PRQR)
www.americanbankingnews.com - April 5 at 11:27 AM
ProQR to Present at Two Upcoming ConferencesProQR to Present at Two Upcoming Conferences
feeds.benzinga.com - April 3 at 7:51 AM
ProQR Therapeutics (PRQR) Upgraded to "Buy" by Zacks Investment ResearchProQR Therapeutics (PRQR) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:16 PM
ProQR Therapeutics NV (PRQR) Receives Average Rating of "Hold" from AnalystsProQR Therapeutics NV (PRQR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 10:16 AM
ProQR to Present at Upcoming Investor ConferenceProQR to Present at Upcoming Investor Conference
finance.yahoo.com - March 13 at 10:03 AM
ProQR Therapeutics (PRQR) Stock Rating Upgraded by ValuEngineProQR Therapeutics (PRQR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 11 at 12:46 AM
ProQR Therapeutics (PRQR) Upgraded to Sell at ValuEngineProQR Therapeutics (PRQR) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 3 at 3:22 PM
ProQR Therapeutics NV (PRQR) Receives Consensus Recommendation of "Hold" from AnalystsProQR Therapeutics NV (PRQR) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 3 at 12:26 PM
ProQR Therapeutics (PRQR) Posts  Earnings Results, Misses Expectations By $0.01 EPSProQR Therapeutics (PRQR) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 1 at 11:18 AM
ProQR Supports Rare Disease Day 2018 and Honors Henri A. TermeerProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
finance.yahoo.com - February 27 at 9:42 AM
Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its IndustryWhere ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - February 26 at 9:34 AM
ProQR Therapeutics (PRQR) Scheduled to Post Quarterly Earnings on MondayProQR Therapeutics (PRQR) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 5:04 AM
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2AFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
finance.yahoo.com - February 12 at 8:57 AM
ProQR Therapeutics (PRQR) Earns Neutral Rating from Chardan CapitalProQR Therapeutics (PRQR) Earns Neutral Rating from Chardan Capital
www.americanbankingnews.com - January 20 at 6:28 AM
ProQR Therapeutics N.V. (PRQR) Receives Consensus Rating of "Buy" from BrokeragesProQR Therapeutics N.V. (PRQR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 12 at 8:02 AM
Zacks Investment Research Downgrades ProQR Therapeutics (PRQR) to HoldZacks Investment Research Downgrades ProQR Therapeutics (PRQR) to Hold
www.americanbankingnews.com - January 9 at 10:36 AM
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technologyProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
finance.yahoo.com - January 8 at 10:22 AM
ProQR Announces Extraordinary General Meeting of ShareholdersProQR Announces Extraordinary General Meeting of Shareholders
finance.yahoo.com - December 27 at 2:33 PM
ProQR Therapeutics N.V. (PRQR) Receives Average Rating of "Buy" from AnalystsProQR Therapeutics N.V. (PRQR) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 18 at 7:58 AM
Comparing Dicerna Pharmaceuticals (DRNA) & ProQR Therapeutics (PRQR)Comparing Dicerna Pharmaceuticals (DRNA) & ProQR Therapeutics (PRQR)
www.americanbankingnews.com - December 8 at 7:42 PM
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis BullosaProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
finance.yahoo.com - November 29 at 10:21 AM
ProQR Therapeutics N.V. (PRQR) Upgraded by Zacks Investment Research to BuyProQR Therapeutics N.V. (PRQR) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 24 at 2:02 PM
ProQR Therapeutics N.V. (PRQR) Receives Average Rating of "Hold" from AnalystsProQR Therapeutics N.V. (PRQR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 23 at 10:16 AM
ProQR Therapeutics N.V. (PRQR) to Post FY2017 Earnings of ($2.06) Per Share, Leerink Swann ForecastsProQR Therapeutics N.V. (PRQR) to Post FY2017 Earnings of ($2.06) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - November 23 at 7:28 AM
ProQR Therapeutics N.V. (PRQR) Issues  Earnings ResultsProQR Therapeutics N.V. (PRQR) Issues Earnings Results
www.americanbankingnews.com - November 21 at 3:34 PM
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary SharesProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
finance.yahoo.com - November 15 at 7:39 AM
ProQR Therapeutics N.V. (PRQR) Downgraded to "Sell" at Zacks Investment ResearchProQR Therapeutics N.V. (PRQR) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 15 at 7:14 AM
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic BlindnessProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
finance.yahoo.com - November 14 at 6:59 AM
ProQR Announces Proposed Public Offering of Ordinary SharesProQR Announces Proposed Public Offering of Ordinary Shares
finance.yahoo.com - November 14 at 6:59 AM
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory BoardProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
globenewswire.com - November 9 at 11:57 AM
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board  ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board  
finance.yahoo.com - November 9 at 11:57 AM
ProQR Therapeutics N.V. (PRQR) Set to Announce Earnings on MondayProQR Therapeutics N.V. (PRQR) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 6 at 6:02 AM
ProQR to Present at EuroTIDES ConferenceProQR to Present at EuroTIDES Conference
finance.yahoo.com - October 31 at 8:08 AM
ProQR Announces Management Change and Key PromotionsProQR Announces Management Change and Key Promotions
finance.yahoo.com - October 27 at 11:31 AM
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis ConferenceProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
finance.yahoo.com - October 24 at 8:50 AM
Analyzing ProQR Therapeutics N.V. (PRQR) and Its RivalsAnalyzing ProQR Therapeutics N.V. (PRQR) and Its Rivals
www.americanbankingnews.com - October 18 at 6:36 AM
Zacks Investment Research Downgrades ProQR Therapeutics N.V. (PRQR) to HoldZacks Investment Research Downgrades ProQR Therapeutics N.V. (PRQR) to Hold
www.americanbankingnews.com - October 7 at 8:38 PM
ProQR to Present at the Chardan Inaugural Gene Therapy ConferenceProQR to Present at the Chardan Inaugural Gene Therapy Conference
finance.yahoo.com - October 7 at 7:34 AM
ProQR Therapeutics N.V. (PRQR) Given Consensus Recommendation of "Buy" by BrokeragesProQR Therapeutics N.V. (PRQR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 9:16 AM
ProQR Therapeutics N.V.s (PRQR) "Buy" Rating Reiterated at HC WainwrightProQR Therapeutics N.V.'s (PRQR) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - October 1 at 7:40 PM
ProQR Therapeutics N.V. (PRQR) Earns "Outperform" Rating from Leerink SwannProQR Therapeutics N.V. (PRQR) Earns "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - October 1 at 6:32 PM
ProQR (PRQR) Updates On QR-010 Phase 1b Topline Data - SlideshowProQR (PRQR) Updates On QR-010 Phase 1b Topline Data - Slideshow
seekingalpha.com - September 28 at 7:47 PM
ProQRs CF candidate QR-010 shows encouraging action in early-stage study, shares up 10% after hoursProQR's CF candidate QR-010 shows encouraging action in early-stage study, shares up 10% after hours
seekingalpha.com - September 26 at 7:07 PM
ProQR Therapeutics N.V. (PRQR) Price Target Raised to $20.00 at JMP SecuritiesProQR Therapeutics N.V. (PRQR) Price Target Raised to $20.00 at JMP Securities
www.americanbankingnews.com - September 26 at 9:32 AM

SEC Filings

ProQR Therapeutics (NASDAQ:PRQR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ProQR Therapeutics (NASDAQ:PRQR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ProQR Therapeutics (NASDAQ PRQR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.